{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T20:49:48Z","timestamp":1791319788905,"version":"4.3.1"},"reference-count":27,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005047","name":"Natural Science Foundation of Liaoning Province","doi-asserted-by":"publisher","award":["2023-MSBA-018"],"award-info":[{"award-number":["2023-MSBA-018"]}],"id":[{"id":"10.13039\/501100005047","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005047","name":"Natural Science Foundation of Liaoning Province","doi-asserted-by":"publisher","award":["2025-MS-023"],"award-info":[{"award-number":["2025-MS-023"]}],"id":[{"id":"10.13039\/501100005047","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","award":["DUT24MS018"],"award-info":[{"award-number":["DUT24MS018"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","award":["DUT26YG110"],"award-info":[{"award-number":["DUT26YG110"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013804","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013804","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.dmd.2026.100406","type":"journal-article","created":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T06:35:56Z","timestamp":1788849356000},"page":"100406","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Liposomal encapsulation redirects the in vivo disposition of paclitaxel: a comparative pharmacokinetic, tissue distribution, and excretion study in rats"],"prefix":"10.1016","volume":"54","author":[{"given":"Guolei","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Miao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yidan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0755-5642","authenticated-orcid":false,"given":"Meiyun","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"27","key":"10.1016\/j.dmd.2026.100406_bib1","doi-asserted-by":"crossref","first-page":"28670","DOI":"10.1021\/acsomega.5c02916","article-title":"\"Nano-Paclitaxel\" unlocking potential and redefining cancer chemotherapy","volume":"10","author":"Muley","year":"2025","journal-title":"ACS Omega"},{"issue":"7","key":"10.1016\/j.dmd.2026.100406_bib2","first-page":"769","article-title":"Paclitaxel anti-cancer therapeutics: from discovery to clinical use","volume":"23","author":"Yu","year":"2025","journal-title":"Chin J Nat Med"},{"issue":"10","key":"10.1016\/j.dmd.2026.100406_bib3","doi-asserted-by":"crossref","first-page":"290","DOI":"10.3390\/nano7100290","article-title":"Practical liposomal formulation for taxanes with polyethoxylated castor oil and ethanol with complete encapsulation efficiency and high loading efficiency","volume":"7","author":"Shigehiro","year":"2017","journal-title":"Nanomaterials (Basel)"},{"issue":"13","key":"10.1016\/j.dmd.2026.100406_bib4","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/S0959-8049(01)00171-X","article-title":"Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation","volume":"37","author":"Gelderblom","year":"2001","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.dmd.2026.100406_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/17588359241236442","article-title":"Treatment with nanosomal paclitaxel lipid suspension versus conventional paclitaxel in metastatic breast cancer patients\u2014a multicenter, randomized, comparative, phase II\/III clinical study","volume":"16","author":"Satheesh","year":"2024","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.dmd.2026.100406_bib6","doi-asserted-by":"crossref","first-page":"11539","DOI":"10.2147\/IJN.S488369","article-title":"Enhanced in vivo stability and antitumor efficacy of pegylated liposomes of paclitaxel palmitate prodrug","volume":"19","author":"Wu","year":"2024","journal-title":"Int J Nanomed"},{"key":"10.1016\/j.dmd.2026.100406_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.colsurfb.2026.115589","article-title":"Liposome-based nanocarriers for ovarian cancer: molecular targeting, therapeutic mechanisms, and clinical translation","volume":"263","author":"Raies","year":"2026","journal-title":"Colloids Surf B Biointerfaces"},{"issue":"25","key":"10.1016\/j.dmd.2026.100406_bib8","doi-asserted-by":"crossref","first-page":"5155","DOI":"10.2174\/0109298673308951240921121345","article-title":"Liposomal nanoformulation-encapsulated paclitaxel for reducing chemotherapy side effects in lung cancer treatments: recent advances and future outlooks","volume":"32","author":"Mohammad-Jafari","year":"2025","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.dmd.2026.100406_bib9","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.jconrel.2023.10.023","article-title":"Ginsenoside Rg3 endows liposomes with prolonged blood circulation and reduced accelerated blood clearance","volume":"364","author":"Xia","year":"2023","journal-title":"J Control Release"},{"issue":"1","key":"10.1016\/j.dmd.2026.100406_bib10","article-title":"Thirty years from FDA approval of pegylated liposomal doxorubicin (Doxil\/Caelyx): an updated analysis and future perspective","volume":"4","author":"Gabizon","year":"2025","journal-title":"BMJ Oncol"},{"issue":"2","key":"10.1016\/j.dmd.2026.100406_bib11","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.jconrel.2012.03.020","article-title":"Doxil\u00ae--the first FDA-approved nano-drug: lessons learned","volume":"160","author":"Barenholz","year":"2012","journal-title":"J Control Release"},{"issue":"12","key":"10.1016\/j.dmd.2026.100406_bib12","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1080\/03639045.2025.2569572","article-title":"Nanocarriers as drug delivery system for chemotherapeutic agents: from inception to clinical implementation","volume":"51","author":"Zubair","year":"2025","journal-title":"Drug Dev Ind Pharm"},{"issue":"2","key":"10.1016\/j.dmd.2026.100406_bib13","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1177\/10781552231208978","article-title":"Innovative strategies for effective paclitaxel delivery: recent developments and prospects","volume":"30","author":"Wile\u0144ski","year":"2024","journal-title":"J Oncol Pharm Pract"},{"key":"10.1016\/j.dmd.2026.100406_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2025.114465","article-title":"Long-acting lipid-based nanomedicines: rethinking from structure-based rational design to in vivo fate evaluation","volume":"389","author":"Tang","year":"2026","journal-title":"J Control Release"},{"key":"10.1016\/j.dmd.2026.100406_bib15","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.ejpb.2020.06.004","article-title":"A physiologically-based nanocarrier biopharmaceutics model to reverse-engineer the in vivo drug release","volume":"153","author":"Nagpal","year":"2020","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1016\/j.dmd.2026.100406_bib16","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2025.1704814","article-title":"How do nanoparticle properties shape pharmacokinetics and pharmacodynamics? A mechanistic review","volume":"16","author":"Peralta-Cuevas","year":"2026","journal-title":"Front Pharmacol"},{"issue":"9","key":"10.1016\/j.dmd.2026.100406_bib17","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1109\/TBME.2016.2632733","article-title":"Assessing the benefits of drug delivery by nanocarriers: a partico\/pharmacokinetic framework","volume":"64","author":"Siegel","year":"2017","journal-title":"IEEE Trans Biomed Eng"},{"issue":"3","key":"10.1016\/j.dmd.2026.100406_bib18","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1021\/acsptsci.0c00011","article-title":"Distinguishing pharmacokinetics of marketed nanomedicine formulations using a stable isotope tracer assay","volume":"3","author":"Skoczen","year":"2020","journal-title":"ACS Pharmacol Transl Sci"},{"issue":"1","key":"10.1016\/j.dmd.2026.100406_bib19","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ijpharm.2011.04.008","article-title":"PEG liposomalization of paclitaxel improved its in vivo disposition and anti-tumor efficacy","volume":"412","author":"Yoshizawa","year":"2011","journal-title":"Int J Pharm"},{"key":"10.1016\/j.dmd.2026.100406_bib20","doi-asserted-by":"crossref","first-page":"553","DOI":"10.2147\/IJN.S228715","article-title":"Preparation, characterization, and pharmacokinetic study of a novel long-acting targeted paclitaxel liposome with antitumor activity","volume":"15","author":"Han","year":"2020","journal-title":"Int J Nanomedicine"},{"issue":"4","key":"10.1016\/j.dmd.2026.100406_bib21","doi-asserted-by":"crossref","first-page":"253","DOI":"10.4103\/ijp.ijp_557_23","article-title":"A novel ultra-performance liquid chromatography detection method development and validation for paclitaxel and its major metabolite in human plasma","volume":"56","author":"Kumar","year":"2024","journal-title":"Indian J Pharmacol"},{"key":"10.1016\/j.dmd.2026.100406_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.jchromb.2020.122127","article-title":"Pretreatment and non-specific binding in ultrafiltration device: impact on protease inhibitor quantification","volume":"1146","author":"Castro","year":"2020","journal-title":"J Chromatogr B"},{"key":"10.1016\/j.dmd.2026.100406_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.talanta.2019.120358","article-title":"Uptake and release profiles of PEGylated liposomal doxorubicin nanoparticles: a comprehensive picture based on separate determination of encapsulated and total drug concentrations in tissues of tumor-bearing mice","volume":"208","author":"Wang","year":"2020","journal-title":"Talanta"},{"issue":"1","key":"10.1016\/j.dmd.2026.100406_bib24","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1097\/FTD.0000000000001016","article-title":"Reproducible quantification of unbound fractions of four beta-lactam antibiotics: ultrafiltration versus microdialysis of spiked healthy donor plasma","volume":"45","author":"Beijer","year":"2023","journal-title":"Therapeutic Drug Monit"},{"issue":"Pt A","key":"10.1016\/j.dmd.2026.100406_bib25","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.jconrel.2015.10.042","article-title":"Stable isotope method to measure drug release from nanomedicines","volume":"220","author":"Skoczen","year":"2015","journal-title":"J Control Release"},{"issue":"5","key":"10.1016\/j.dmd.2026.100406_bib26","first-page":"1035","article-title":"Comparative in vivo studies with paclitaxel and liposome-encapsulated paclitaxel","volume":"12","author":"Cabanes","year":"1998","journal-title":"Int J Oncol"},{"key":"10.1016\/j.dmd.2026.100406_bib27","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.3389\/fonc.2020.01731","article-title":"Population pharmacokinetics and exposure-safety relationship of paclitaxel liposome in patients with non-small cell lung cancer","volume":"10","author":"Zhou","year":"2020","journal-title":"Front Oncol"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955626006756?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955626006756?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T19:50:02Z","timestamp":1791316202000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955626006756"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":27,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S0090955626006756"],"URL":"https:\/\/doi.org\/10.1016\/j.dmd.2026.100406","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Liposomal encapsulation redirects the in vivo disposition of paclitaxel: a comparative pharmacokinetic, tissue distribution, and excretion study in rats","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dmd.2026.100406","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Society for Pharmacology and Experimental Therapeutics. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"100406"}}